Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Simcere Pharmaceutical Group
Dr. Zang Jingwu to lead Simcere's Research & Development Team
NANJING, China, Oct. 15, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Dr. Zang Jingwu as Chief Scientific Officer of the Company, effective October 8, 2013.
Dr. Zang received his medical degree from Shanghai JiaoTong University School of Medicine. He earned a PhD from the University of Brussels and was a post-doctoral fellow at Harvard Medical School. Dr. Zang later joined the faculty of Baylor College of Medicine as a professor of Neurology and holds a medical license in the State of Texas in US. In his career in China, Dr. Zang was the founding director of the Institute of Health Sciences and Institute Pasteur Shanghai of the Chinese Academy of Sciences. In 2007, Dr. Zang joined GSK as Senior VP and head of GSK's R&D Centre in China; and in 2012, he held one more position as the global head of Neurosciences Therapy Area in GSK.
Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We are extremely pleased that Jingwu will be joining the Simcere management team to lead our R&D efforts. With his rich industry experience and solid knowledge of new drug development, we are confident that Jingwu will be an important contributor to Simcere as we continue to broaden our pipeline of innovative medicines."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Simcere Pharmaceutical Group
In the United States:
Brunswick Group LLC
©2012 PR Newswire. All Rights Reserved.